Skip to main content

Day: February 3, 2022

Oma Savings Bank Plc has applied to the Finnish Financial Supervisory Authority (FIN-FSA) for the application of IRB method in capital adequacy

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 3 FEBRUARY 2022 AT 14.30 P.M. EET, OTHER INFORMATION DISCLOSED TO THE RULES OF THE EXCHANGEOma Savings Bank Plc has applied to the Finnish Financial Supervisory Authority (FIN-FSA) for the application of IRB method in capital adequacy The Board of Directors of Oma Savings Bank Plc (OmaSp or the Company) has approved the IRB permit application package and the Company has decided to initiate a permit process with the Finnish Financial Supervisory Authority (FIN-FSA) on the application of IRB method in capital adequacy. In the first stage, the Company applies permission to apply an internal risk classification under the IRB method to calculate capital requirements for retail credit risk liabilities. Later, the Company will also apply for a permit for corporate liabilities as well as renewable...

Continue reading

Graybug to Participate in Three Upcoming Medical and Investor Conferences

BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) — Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its participation in three upcoming medical and investor conferences:Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition – Veeral Sheth, MD, to present on “Safety and Durability of Intravitreal Sunitinib Malate Depot (GB-102) in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase 2B)” on February 11, 2022, at 8:30 a.m. ET / 7:30 am CT / 5:30 a.m. PT. Dr. Sheth will discuss the full-data analysis and highlight patient cases from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration, Graybug’s proprietary formulation...

Continue reading

Sparton Says: “Let the Green Games Begin!”

Beijing Highlights Renewable Energy at Winter Olympics TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) — Sparton Resources Inc. (TSXV: SRI) (“Sparton” or the “Company“) is pleased to report that the Zhangbei wind and solar renewable energy project will provide 100 percent of the energy used during the Beijing 2022 Olympic Winter Games which begin today. Zhangbei, a county in Hebei Province in north China, is one of the four places where power stations were built to convert wind, solar and other green energies into flexible direct current. An integral Part of the Zhangbei Project is an 8 Megawatt hour vanadium flow battery built by VRB Energy Inc.’s predecessor company and commissioned with funds provided by Sparton subsidiary, VanSpar Mining Inc. (Please see Sparton News Release dated February 25, 2016, for background.) Zhangbei...

Continue reading

WPD Pharmaceuticals Announces Appointment of New Director

VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that the Company appointed Mr. Romuald Harwas as a director of the Company, effective February 2, 2022. The appointment of Mr. Harwas filled the vacancy created by the prior resignation of Walter Klemp on October 14, 2021. Mr. Harwas brings several years of experience and expertise in finance to WPD’s Board of Directors. He began his career from the position of financial analyst, was a management accountant, financial controller and then CFO and a board member of limited companies. In Poland, he worked at TVN, Luxmed and Synektik. Romuald spent more than six years abroad, working for among others, Australian syndicate Bradken. He has led transition processes of companies...

Continue reading

Applied Materials Announces Q1 FY2022 Earnings Webcast

SANTA CLARA, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) — Applied Materials, Inc. will hold a webcast to discuss its first quarter of fiscal 2022 financial results on Wednesday, Feb. 16, 2022 at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast will be accessible via the Applied Materials website at: https://ir.appliedmaterials.com. A replay will be available on the same day beginning at 8:00 p.m. ET / 5:00 p.m. PT. About Applied MaterialsApplied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible a better future. Learn more at www.appliedmaterials.com. Contact:Ricky...

Continue reading

Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

Biotech Company Strengthens Board Experience VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s Board of Directors. Dr. Hale is a pharmaceutical scientist and executive, as well as a global health social entrepreneur. She currently serves as Chair of the Board of the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization leading the psychedelics sector in new medicine development. MAPS works to raise awareness of psychedelics and help scientists design, fund and obtain regulatory approval of studies...

Continue reading

Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics

Rewrite Therapeutics’ proprietary and versatile DNA writing platform enables a range of novel genome editing strategies Acquisition further expands Intellia’s industry-leading genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR/Cas9 and base editing technologiesCAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced the acquisition of Rewrite Therapeutics, Inc. (Rewrite), a private biotechnology company focused on advancing novel DNA writing technologies. Rewrite has developed promising new tools for genome editing, including DNA writing via CRISPR/Cas9-guided polymerases. Founded by pioneering scientists...

Continue reading

Visionstate Expands Sales Staff to Meet Increasing Demand for IoT Technology to Address COVID-19

EDMONTON, Alberta, Feb. 03, 2022 (GLOBE NEWSWIRE) — Visionstate Corp. (TSXV: VIS) (“Visionstate” or the “Company”) is pleased to announce it has hired a new Director of Sales to address the growing demand for Visionstate’s IoT (Internet of Things) technology that is designed to track and monitor cleaning and maintenance activities in the on-going fight to contain the spread of viruses such as COVID-19. The Visionstate team welcomes Shannon Moore in her role as Director of Sales for the Company’s IoT division, a wholly-owned subsidiary of Visionstate Corp. Shannon will be responsible for executing the sales strategy and working with Visionstate’s global partners to facilitate sales for the Company’s proprietary WANDA™ technology which is focussed on cleaning and maintenance compliance. Shannon has more than 20 years of experience...

Continue reading

CoreCard Corporation Schedules Fourth Quarter 2021 Earnings Release and Conference Call

NORCROSS, Ga., Feb. 03, 2022 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, intends to hold an investor conference call on February 15, 2022, at 11:00 A.M. Eastern Time in conjunction with the company’s earnings release for the quarter ended December 31, 2021. The company plans to issue a press release with the financial results for the period before the market opens on February 15, 2022. Interested investors are invited to attend the conference call by accessing the webcast at https://www.webcast-eqs.com/corecard02152022/en or by dialing 1-877-407-0890. As part of the conference call CoreCard will be conducting a question-and-answer session where participants are invited to email their...

Continue reading

Axogen to Participate at Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced it will participate in two investor conferences in February. Karen Zaderej, chairman, CEO, and president will participate in a fireside discussion at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 1:25 p.m. ET. To listen to the live event, please contact your BTIG representative with interest. Ms. Zaderej will also participate in a fireside discussion at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 1:40 p.m. ET. The discussion will be webcast live and can be accessed through the Investors page...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.